Pharmaceutical companies are starting to design clinical trials for cancer treatments using data on cancer genetics to pinpoint which patients are more likely to respond to each drug, according to MIT's Technology Review. Emily Singer writes that doctors are hoping to be able to treat patients with specific drugs according to the genetic profile of their illness, and which mutations are affecting their individual tumors. Researchers at the Wellcome Trust Sanger Institute's Cancer Genome Project are collaborating with researchers at Massachusetts General Hospital to screen 400 compounds on 1,000 cancer cell lines derived from various tumors, Singer says. "Collectively, the cells possess about 70 cancer-linked genetic mutations, about 50 to 80 percent of the mutations that have been uncovered to date," she adds.
Pharma Capitalizes on Cancer Genetics
Jul 21, 2010